476 completed, 122 terminated, 81 unknown, 24 withdrawn. 452 Phase 2, 224 Phase 1, 85 Phase 3, 17 Not applicable, 14 Phase 4.
Follow Erlotinib Hydrochloride: new trials by email Literature Review of Erlotinib Hydrochloride trials Research Report on Erlotinib Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-07-01 | 2026-08-03 |
| Erlotinib for Hepatocellular Carcinoma Chemoprevention erlotinib hydrochloride, Placebo - Cirrhosis, Liver, Advanced Liver Fibrosis | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 60 | 2026-12-01 | 2026-06-24 |
| Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population Celecoxib, Erlotinib Hydrochloride, Imaging Procedure - Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 25 | 2025-08-07 | 2026-10-01 |
| Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors Erlotinib, Lenvatinib, Axitinib - Neoplasms | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2025-07-15 | 2025-07-16 | |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 104 | 2025-02-06 | 2026-04-23 |
| Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients Nintedanib, gefitinib, erlotinib, afatinib, osimertinib - Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 1 / Phase 2 | Recruiting | China Medical University Hospital | 20 | 2024-02-23 | 2025-01-23 |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. lorlatinib, crizotinib, brigatinib - Non-Small Cell Lung Cancer | Completed | Pfizer | 5279 | 2023-06-23 | 2025-03-30 | |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications BBI-355, Erlotinib, Futibatinib - Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | Phase 1 | Terminated | Boundless Bio, Inc. | 85 | 2023-03-24 | 2026-08-19 |
| A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer bevacizumab, erlotinib - Solid Tumors, Advanced Solid Tumors | Phase 2 | Unknown | Asan Medical Center | 32 | 2023-01-02 | 2023-06-15 |
| KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II Alectinib, Atezolizumab, Erlotinib - Solid Tumor, Advanced Solid Tumor | Active not recruiting | Seoul National University Bundang Hospital | 1000 | 2022-09-28 | 2026-09-30 | |
| To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer 30 μg OBI-833/100 μg OBI-821, Erlotinib (150 mg daily) - Non-small Cell Lung Cancer | Phase 2 | Recruiting | OBI Pharma, Inc | 60 | 2022-07-27 | 2025-08-03 |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer Atezolizumab, Bevacizumab, Biopsy Procedure - Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 65 | 2022-06-10 | 2026-09-29 |
| Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Pemetrexed 500 MG, Erlotinib - Biliary Tract Cancer | Phase 2 | Unknown | Samsung Medical Center | 44 | 2021-07-09 | 2022-06-15 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study Bevacizumab, Erlotinib, Gefitinib - NSCLC | Unknown | Guangdong Association of Clinical Trials | 272 | 2020-10-07 | 2020-10-20 | |
| Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC Almonertinib, Erlotinib, Cisplatin - Non-Small Cell Lung Cancer Stage IIIA | Phase 2 | Unknown | The First Affiliated Hospital of Guangzhou Medical University | 168 | 2020-10-01 | 2020-07-02 |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling Alectinib, Atezolizumab, Avelumab - Cancer, Tumors | Phase 2 | Recruiting | Ulrik Lassen | 300 | 2020-08-24 | 2025-07-25 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation GDC-6036, Atezolizumab, Cetuximab - Non-Small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Active not recruiting | Genentech, Inc. | 498 | 2020-07-29 | 2026-08-28 |
| PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study PD-1 inhibitor, Chemotherapy Drugs, Cancer - Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events | Unknown | Sungkyunkwan University | 4724 | 2020-07-01 | 2020-05-28 | |
| Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation Osimertinib, Alectinib 150 MG, Crizotinib 250 MG - Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Recruiting | Hunan Province Tumor Hospital | 6000 | 2020-04-16 | 2024-10-22 |
Showing 20 of 732. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (307) · Lung Neoplasms (111) · Pancreatic Neoplasms (70) · Neoplasms (56) · Neoplasm Metastasis (32) · Brain Neoplasms (31) · Head and Neck Neoplasms (26) · Breast Neoplasms (25) · Squamous Cell Carcinoma of Head and Neck (25) · Glioblastoma (24) · Adenocarcinoma of Lung (23) · Gliosarcoma (22) · Colorectal Neoplasms (18) · Carcinoma, Hepatocellular (17) · Adenocarcinoma, Bronchiolo-Alveolar (16)
National Cancer Institute (NCI) (73) · Hoffmann-La Roche (61) · M.D. Anderson Cancer Center (40) · Genentech, Inc. (16) · Eli Lilly and Company (13) · OSI Pharmaceuticals (12) · SCRI Development Innovations, LLC (12) · Vanderbilt-Ingram Cancer Center (10) · Dana-Farber Cancer Institute (9) · Memorial Sloan Kettering Cancer Center (9) · Pfizer (9) · UNC Lineberger Comprehensive Cancer Center (9) · Merck Sharp & Dohme LLC (7) · SWOG Cancer Research Network (7) · Samsung Medical Center (7)
United States (453) · China (66) · South Korea (65) · Spain (64) · Canada (63) · France (60) · Italy (56) · United Kingdom (54) · Germany (49) · Taiwan (42) · Netherlands (38) · Belgium (36) · Australia (32) · Poland (31) · Brazil (26)
Helena Yu, MD (4) · John D. Hainsworth, MD (4) · Ingrid Mayer, MD (3) · Jennifer J. Wheler, MD (3) · Pasi A Janne, MD, PhD (3) · Philip Philip (3)
PMID 33067126, PMID 22586319, PMID 23442309, PMID 23782814, PMID 26768165, PMID 37794220, PMID 39863139, PMID 11099318, PMID 11948464, PMID 14520092, PMID 15258838, PMID 15284258, PMID 16204015, PMID 16622264, PMID 16740761, PMID 16805854, PMID 16990388, PMID 17050876, PMID 17150016, PMID 17452677, PMID 17470864, PMID 17538162, PMID 17538163, PMID 17699864, PMID 17876014, PMID 18056187, PMID 18245491, PMID 18272024, PMID 18281658, PMID 18438878, PMID 18496750, PMID 18591547, PMID 18612161, PMID 18829515, PMID 18955445, PMID 19047285, PMID 19075262, PMID 19201650, PMID 19204207, PMID 19299235, PMID 19415121, PMID 19494788, PMID 19523815, PMID 19562254, PMID 19616281, PMID 19624979, PMID 19965914, PMID 20089114, PMID 20130876, PMID 20156778
U10CA032102 (10), 2008 (8), P30CA068485 (7), 2014 (6), P30CA015083 (6), 2005 (5), 2009 (5), P30CA006973 (5), P30CA043703 (5), P30CA093373 (5), N01CM62201 (4), P30CA016086 (4), P30CA016672 (4), U10CA021115 (4), U10CA031946 (4)